Abstract
Novokinin (Arg-Pro-Leu-Lys-Pro-Trp) is a potent hypotensive peptide previously designed based on the structure of ovokinin(2-7) (Arg-Ala-Asp-His-Pro-Phe), a vasorelaxing and hypotensive peptide derived from ovalbumin. Novokinin exhibited an affinity for the angiotensin AT(2) receptor (Ki=7.35 microM). Novokinin significantly lowered systolic blood pressure at a dose of 0.03 and 0.1 mg/kg after intravenous and oral administration, respectively, in spontaneously hypertensive rats (SHRs), and the hypotensive activity was blocked by PD123319, an antagonist of the AT(2) receptor. Novokinin lowered blood pressure in C57BL/6J mice after oral administration at a dose of 50 mg/kg. However, in AT(2) receptor-deficient mice, novokinin did not reduce blood pressure. These results demonstrate that the hypotensive activity of novokinin is mediated by the AT(2) receptor. The hypotensive activity of novokinin in SHRs was completely blocked by indomethacin and CAY10441, an inhibitor of cyclooxygenase and an antagonist of the prostaglandin IP receptor, respectively. These suggest that the hypotensive activity is mediated by prostacyclin and the IP receptor downstream of the AT(2) receptor.
References
Dec 31, 1991·Biochemical and Biophysical Research Communications·S E WhitebreadM de Gasparo
May 16, 1991·Nature·K SasakiT Inagami
Oct 26, 1995·Nature·L HeinB K Kobilka
Oct 26, 1995·Nature·T IchikiT Inagami
Jun 1, 1995·Clinical Cardiology·G P Guthrie
Aug 11, 1995·The Journal of Biological Chemistry·T SugayaA Otsuka
Nov 21, 1994·Neuroreport·L NäveriJ M Saavedra
Mar 19, 1993·Regulatory Peptides·M L WebbT J Murphy
Jul 1, 1999·FEBS Letters·N MatobaM Yoshikawa
Oct 8, 1999·The Journal of Clinical Investigation·Y TsutsumiT Iwasaka
Sep 20, 2000·Journal of Hypertension·M TamuraP R Myers
Aug 7, 2002·Bioscience, Biotechnology, and Biochemistry·Yuko YamadaMasaaki Yoshikawa
May 1, 2004·Circulation·Wendy W BatenburgA H Jan Danser
Jun 5, 2004·Regulatory Peptides·Phouangmala ScruggsNae J Dun
Nov 13, 2004·Journal of Medicinal Chemistry·Yiqian WanMathias Alterman
Jan 18, 2005·Journal of Cardiovascular Pharmacology·Sandra Y FukadaAna M de Oliveira
Nov 1, 2005·European Journal of Pharmacology·Dimitry Baranov, William M Armstead
Nov 4, 2006·Journal of Hypertension·Carmine SavoiaRhian M Touyz
Citations
Jan 8, 2008·Bioscience, Biotechnology, and Biochemistry·Yuko YamadaMasaaki Yoshikawa
Feb 15, 2014·BioMed Research International·Subhadeep ChakrabartiJianping Wu
Aug 26, 2014·Pharmacological Reports : PR·Bożena BądzyńskaElżbieta Kompanowska-Jezierska
Jan 16, 2013·International Journal of Hypertension·Marie-Odile Guimond, Nicole Gallo-Payet
Mar 2, 2010·Peptides·Yuko YamadaMasaaki Yoshikawa
May 26, 2009·Peptides·Kousaku OhinataMasaaki Yoshikawa
Feb 9, 2008·FEBS Letters·Kousaku OhinataMasaaki Yoshikawa
Sep 10, 2010·The Journal of Investigative Dermatology·Stéphanie GohinBérengère Fromy
Dec 17, 2008·Peptides·Yuko YamadaMasaaki Yoshikawa
Jan 30, 2008·Peptides·Yuko YamadaMasaaki Yoshikawa
Aug 25, 2015·Peptides·Masaaki Yoshikawa
Dec 3, 2013·Journal of Pharmacological Sciences·Takahiro UchidaYoshiki Sakai
Dec 18, 2013·Pain·Claus Dieter SchuhKlaus Scholich
Nov 7, 2016·Alcohol·Yang ZhangQiang Chen
Oct 14, 2017·Canadian Journal of Physiology and Pharmacology·D PechlivanovaA Stoynev
Jul 9, 2008·Hypertension·Klaus HöcherlMichael Bucher
Jan 27, 2019·Nutrients·Anna Mas-CapdevilaBegoña Muguerza
Apr 18, 2021·Bioscience, Biotechnology, and Biochemistry·Kazuhito AkamaAkio Nishikawa
Apr 3, 2021·Molecular Pharmacology·Arina RanjitAli Aghazadeh-Habashi